Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5983_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
12.10.2026
Размер:
6 Мб
Скачать
☆
38
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
        -
      

(Kirkham and Davis, 2015). Despite promising laboratorial outcomes, data

      
treatment are still limited (Mehta, 2018).
In addition to physical activity , both cancer and the cardiotoxicity caused
by chemotherapy drugs can be modulated by healthy and balanced diets and
nutritional therapies, based on antioxidant supplements, because they are
     
and, consequently, reducing the oxidative stress (Saha et al., 2017).

-



-
   


have been used in medicine to prevent and treat several diseases, including
        

      
2011).
-


(Su et al., 2022).
Nanoparticles containing chemotherapy drugs act by targeting the tumor
microenvironment and niche, releasing the active ingredients in the tumor
tissues, thus reducing toxicity in heart tissues (Su et al., 2022).

micelles, dendrimers, and hydrogels) used as drug carriers are the prevention

-

in vital organs, such as the heart (Su et al., 2022).
Advances for Medical Applications in Breast Cancer and Cardiotoxicity
39
       
     
  
in-vitro  


          
       
        


FIGURE 2.1 
2.1.1 BENEFITS OF PHYSICAL ACTIVITY DURING CHEMOTHERAPY
IN PATIENTS WITH BREAST CANCER
           





         

Exercises can reduce breast cancer and its recurrence and help increase


         
        
40
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2

          
 

        
(Scott et al., 2018).
  
physical exercise during chemotherapy treatments (de Boer et al., 2017).
       
    
sessions (de Boer et al., 2019).
-

         

al., 2021), and only one study applied the intervention in a tele-monitored
     
         


   

         
 


      



2019).
        

          
  
        

interventions based on exercises can reduce the cardiotoxicity caused by

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
41

     

        



-
      



2018b).
        -
-




     


exercises can prevent anthracycline-induced cardiotoxicity and anti-HER2


         


      
  
-







          
42
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
        





  
  
    



        


        
         
          



diverse aspects.
2.1.2 PHYSICAL EXERCISE IN THE PREVENTION OF
CARDIOTOXICITY
-

endometrium, esophagus, stomach, kidney, bladder, and lung, and reduces
mortality in patients that survived breast, prostate, colon, and rectum neopla-

      
these patients (Herdy et al., 2014).
          
-

      

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
43
    
-

       -
     


        
      

   


anthracycline-induced toxicity in the cardiac muscle are still lacking (Maia

         

       -

        
        


group (n = 13) compared to the control (n = 11), despite improvements in



        
    
     -
 
2018).
On the other hand, a previous and very similar study conducted by the
        





44
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
         
        
       

          

(VO
2 max


  
2 peak
in the intervention group.

        

and cardiac output (Hornsby et al., 2014).

       
      -
           
-
  


2 max
-





A later research study conducted by Hiraoui et al. (2019) assessed 32


         -
   
        

       
   


-

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
45





are more likely to complete chemotherapy (An et al., 2021).
-
lute VO
2 peak





          
  
       
cardiorespiratory responses.
 

-



        







-



         
-

      
(Antunes et al., 2019).
46
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-



     


by echocardiogram (Jacquinot et al., 2017).

-



  

-









elucidate the pathophysiological mechanisms involved, and determine the

2.1.3 NUTRITIONAL SUPPLEMENTATION IN BREAST CANCER AND
PROTECTION AGAINST CARDIOTOXICITY

and Suh, 2011), vitamin D (Lee et al., 2021), carotenoids such as curcumin

        
    Ganoderma lucidum (Xu et al.,

such as Ceylon cinnamon (Cinnamomum zeylanicum Blume) (Sandamali et
       
Advances for Medical Applications in Breast Cancer and Cardiotoxicity
47


in-vivo animal

et al., 2020). It should also be noted that, depending on the type and concen-





  -
genesis in animal models (Smolarek and Suh, 2011).
          


        
     

Suh, 2011).
        
reported as a cardioprotective agent. It reduced Dox-induced cardiotoxicity,
diminished ROS and mitochondrial damage, and did not diminish Dox-
      
(Lee et al., 2021).
        
Curcuma longa





          






oral administration (Saghatelyan et al., 2020).